Royalty Pharma plc — Director's Dealing 2022

May 31, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Royalty Pharma plc (RPRX)
CIK: 0001802768
Period of Report: 2022-05-27

Reporting Person: Reddoch James F. (EVP & Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-05-27	Class A Ordinary Shares	S	75000	$41.0801	Disposed	1020800	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Class A Ordinary Shares	25030	Indirect

Footnotes

F1: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.97 to $41.16 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.